Loading clinical trials...
Loading clinical trials...
A Phase 1 Study of AGEN2373, an Anti-CD137 Monoclonal Antibody, as Monotherapy and in Combination With AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody, in Patients With Advanced Cancer
Conditions
Interventions
AGEN2373
Botensilimab
Locations
12
United States
University of Southern California Norris Comprehensive Cancer Center/ Hoag
Los Angeles, California, United States
University of Colorado Anschutz Medical Campus
Aurora, Colorado, United States
University of Miami
Coral Gables, Florida, United States
Moffitt Cancer Center
Tampa, Florida, United States
Atlantic Health System
Morristown, New Jersey, United States
Roswell Park Comprehensive Cancer Care
Buffalo, New York, United States
Start Date
September 26, 2019
Primary Completion Date
February 22, 2024
Completion Date
November 30, 2024
Last Updated
January 13, 2025
NCT04657068
NCT04900818
NCT05004116
NCT06440005
NCT07246954
NCT06242470
Lead Sponsor
Agenus Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions